Crescita Therapeutics has granted Taro Pharmaceuticals an exclusive license to the rights to sell and distribute Pliaglis, a topical anesthetic that sets into a peelable mask, in the U.S. market. The license agreement also includes a second-generation, patent-ending enhanced version of Pliaglis. Crescita will retain all rights to the product in Canada and Mexico.
Pliaglis is a topical local anesthetic ( lidocaine 7%/tetracaine 7%) that can be used prior to superficial aesthetic treatments, such as injectables and laser procedures. The product features a proprietary phase-changing topical cream “Peel” technology, which consists of a drug-containing cream that, once applied to a patient's skin, dries to form a pliable layer that releases drug into the skin. Following the application period, Pliaglis is removed from the skin allowing the dermatological procedure to be performed with minimal to no pain.
“We are delighted to have Taro as our new licensing partner for Pliaglis in the U.S.,” said Dan Chicoine, executive chairman and interim CEO of Crescita. “Taro is a leading supplier of topical dermatological products in the U.S. We look forward to working with Taro to not only reintroduce Pliaglis to the U.S. market, but to also obtain FDA approval for the patent-pending Enhanced Formulation.”
